Atrium Therapeutics to Present ATR 1072 Nonclinical PRKAG2 Data at AHA Sessions
閱讀少於1分鐘
Atrium Therapeutics will present nonclinical findings showing its investigational therapy’s mouse surrogate reversed cardiac glycogen buildup and improved other PRKAG2 syndrome features.
Key Highlights:
- Atrium will present the findings at the HCMS during the AHA Scientific Sessions on November 6, 2026, in Chicago.
- In a company-developed mouse model, a single dose of mATR 1072 reversed cardiac glycogen accumulation after disease features were established.
- Treatment also improved cardiac hypertrophy and ECG parameters, supporting the scientific rationale for ATR 1072.
- Atrium expects initial proof-of-concept data from its ongoing Phase 1/2 Corventis trial in the second half of 2027.
Original SEC Filing: Atrium Therapeutics, Inc. [ RNA ] - 8-K - Nov. 02, 2026
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.